HEM: Analysis of a New Biomarker for Prostate Cancer Diagnosis
Sponsor
Corporacion Parc Tauli (Other)
Overall Status
Unknown status
CT.gov ID
NCT01819740
Collaborator
(none)
28
1
Study Details
Study Description
Brief Summary
The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
28 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Study Start Date
:
Apr 1, 2013
Anticipated Primary Completion Date
:
Apr 1, 2013
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| patients with suspected prostate cancer
|
Other: determine the levels of the "HEM" substance in seminal plasma
|
Outcome Measures
Primary Outcome Measures
- substance "HEM" concentration in seminal plasma (mEq/L measured by spectro-photometry [1 hour]
Eligibility Criteria
Criteria
Ages Eligible for Study:
45 Years
to 75 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Clinical or laboratory suspected of prostate cancer
Exclusion Criteria:
- Inability to ejaculate
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Universitario Parc Taulí | Sabadell | Barcelona | Spain | 08208 |
Sponsors and Collaborators
- Corporacion Parc Tauli
Investigators
- Principal Investigator: Miriam Barrio-Muñoz, Hospital Universitario Parc Tauli de Sabadell. Spain
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
MIRIAM BARRIO MUÑOZ,
UROLOGY RESIDENT,
Hospital de Sabadell
ClinicalTrials.gov Identifier:
NCT01819740
Other Study ID Numbers:
- CSPT/URO/2013/PROSTATE
First Posted:
Mar 28, 2013
Last Update Posted:
Mar 28, 2013
Last Verified:
Mar 1, 2013
Additional relevant MeSH terms: